241 related articles for article (PubMed ID: 24170256)
1. An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.
Hobbs D; Karagianis J; Treuer T; Raskin J
Drugs R D; 2013 Dec; 13(4):281-8. PubMed ID: 24170256
[TBL] [Abstract][Full Text] [Related]
2. Design, development and in-vitro evaluation of diclofenac taste-masked orodispersible tablet formulations.
Guhmann M; Preis M; Gerber F; Pöllinger N; Breitkreutz J; Weitschies W
Drug Dev Ind Pharm; 2015 Apr; 41(4):540-51. PubMed ID: 24495274
[TBL] [Abstract][Full Text] [Related]
3. Formulation and evaluation of clozapine orally disintegrating tablets prepared by direct compression.
Olmez SS; Vural I; Sahin S; Ertugrul A; Capan Y
Pharmazie; 2013 Feb; 68(2):110-6. PubMed ID: 23469682
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets.
Kokott M; Lura A; Breitkreutz J; Wiedey R
Eur J Pharm Biopharm; 2021 Nov; 168():122-130. PubMed ID: 34474110
[TBL] [Abstract][Full Text] [Related]
5. A pharmaceutical study on chlorzoxazone orodispersible tablets: formulation, in-vitro and in-vivo evaluation.
Moqbel HA; ElMeshad AN; El-Nabarawi MA
Drug Deliv; 2016 Oct; 23(8):2998-3007. PubMed ID: 26828616
[TBL] [Abstract][Full Text] [Related]
6. Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application.
Bin LK; Helaluddin ABM; Islam Sarker MZ; Mandal UK; Gaurav A
Pak J Pharm Sci; 2020 Mar; 33(2):551-559. PubMed ID: 32276897
[TBL] [Abstract][Full Text] [Related]
7. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
8. Effect of co-processed excipient type on properties of orodispersible tablets containing captopril, tramadol, and domperidone.
Tranová T; Loskot J; Navrátil O; Brniak W; Mužíková J
Int J Pharm; 2023 Apr; 636():122838. PubMed ID: 36921743
[TBL] [Abstract][Full Text] [Related]
9. [Pharmaceutical formulations and adherence to pharmacological treatment in psychiatry: the example of oral disintegrating tablet of olanzapine].
Cecchi C; Canonico PL
Riv Psichiatr; 2012; 47(1):30-9. PubMed ID: 22358215
[TBL] [Abstract][Full Text] [Related]
10. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
Gowda V; Pabari RM; Kelly JG; Ramtoola Z
Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
[TBL] [Abstract][Full Text] [Related]
11. Testing the disintegration and texture-related palatability predictions for orodispersible tablets using an instrumental tool coupled with multivariate analysis: Focus on process variables and analysis settings.
Iovanov R; Cornilă A; Bogdan C; Hales D; Tomuță I; Achim M; Tăut A; Iman N; Casian T; Iurian S
Eur J Pharm Sci; 2024 Jul; 198():106801. PubMed ID: 38754594
[TBL] [Abstract][Full Text] [Related]
12. The influence of the API properties on the ODTs manufacturing from co-processed excipient systems.
Krupa A; Jachowicz R; Pędzich Z; Wodnicka K
AAPS PharmSciTech; 2012 Dec; 13(4):1120-9. PubMed ID: 22941425
[TBL] [Abstract][Full Text] [Related]
13. Investigating the Impact of Co-processed Excipients on the Formulation of Bromhexine Hydrochloride Orally Disintegrating Tablets (ODTs).
Woyna-Orlewicz K; Brniak W; Tatara W; Strzebońska M; Haznar-Garbacz D; Szafraniec-Szczęsny J; Antosik-Rogóż A; Wojteczko K; Strózik M; Kurek M; Jachowicz R; Mendyk A
Pharm Res; 2023 Dec; 40(12):2947-2962. PubMed ID: 37726407
[TBL] [Abstract][Full Text] [Related]
14. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
[TBL] [Abstract][Full Text] [Related]
15. Risperidone oral disintegrating mini-tablets: A robust-product for pediatrics.
El-Say KM; Ahmed TA; Abdelbary MF; Ali BE; Aljaeid BM; Zidan AS
Acta Pharm; 2015 Dec; 65(4):365-82. PubMed ID: 26677895
[TBL] [Abstract][Full Text] [Related]
16. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
[TBL] [Abstract][Full Text] [Related]
17. Flexible modelling of the dissolution performance of directly compressed tablets.
Maclean N; Armstrong JA; Carroll MA; Salehian M; Mann J; Reynolds G; Johnston B; Markl D
Int J Pharm; 2024 May; 656():124084. PubMed ID: 38580072
[TBL] [Abstract][Full Text] [Related]
18. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
Al-Khattawi A; Mohammed AR
Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
[TBL] [Abstract][Full Text] [Related]
19. A Promising Single Oral Disintegrating Tablet for Co-Delivery of Pitavastatin Calcium and Lornoxicam Using Co-Processed Excipients: Formulation, Characterization and Pharmacokinetic Study.
Teaima MH; Abdel-Haleem KM; Osama R; El-Nabarawi MA; Elnahas OS
Drug Des Devel Ther; 2021; 15():4229-4242. PubMed ID: 34675486
[TBL] [Abstract][Full Text] [Related]
20. Application of SeDeM expert systems in preformulation studies of pediatric ibuprofen ODT tablets.
Sipos E; Oltean AR; Szabó ZI; Rédai EM; Nagy GD
Acta Pharm; 2017 Jun; 67(2):237-246. PubMed ID: 28590910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
